AKT1 and cancer: Aberrant activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signalling pathway has been identified as a key mechanism of resistance to treatment in cancer, including ET with or without a CDK4/6 inhibitor in MBC patients [5–9].